N-L-gamma-谷氨酰-L-亮氨酸 | 2566-39-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 亮氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-L-gamma-谷氨酰-L-亮氨酸
• 中文别名: (2S)-2-[[(4S)-4-氨基-5-羟基-5-氧代戊酰]氨基]-4-甲基戊酸
• 英文名称: (S)-2-((S)-4-Amino-4-carboxy-butyrylamino)-4-methyl-pentanoic acid
• 英文别名: (S)-2-amino-5-((S)-1-carboxy-3-methylbutylamino)-5-oxopentanoic acid；γ-L-glutamyl-L-leucine；L-γ-glutamyl-L-leucine；γ-glutamyl-leucine；γ-glutamylleucine；glutamyl‐leucine；gamma-Glu-leu；(2S)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-4-methylpentanoic acid
• CAS: 2566-39-4
• 化学式: C₁₁H₂₀N₂O₅
• 分子量: 260.29
• InChiKey: MYFMARDICOWMQP-YUMQZZPRSA-N

物化性质

• 熔点：
  185 °C
• 沸点：
  550.6±50.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)
• 溶解度：
  甲醇（微溶）、水（微溶）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• WGK Germany：
  3
• 储存条件：
  2-8°C

制备方法与用途

H-γ-Glu-Leu-OH是一种由γ-谷氨酸和亮氨酸组成的二肽，其末端带有羟基基团。

反应信息

• 作为反应物：
  描述：

  N-L-gamma-谷氨酰-L-亮氨酸 在 recombinant Pseudomonas nitroreducens IFO12694 γ-glutamyltranspeptidase 作用下， 反应 0.03h， 生成 L-亮氨酸 、 L-谷氨酸
  参考文献：
  名称：

  Molecular Cloning and Characterization of γ-Glutamyltranspeptidase fromPseudomonas nitroreducensIFO12694

  摘要：

  与其它γ-谷氨酰转肽酶（GGT）相比，来自IFO12694的铜绿假单胞菌（PnGGT）展现出更高的水解活性而非转移活性。PnGGT对大多数L-氨基酸和常在GGT转移反应中用作标准γ-谷氨酰受体的甘氨酰甘氨酸表现出极低活性。作为γ-谷氨酰受体，PnGGT的优先底物为甲胺、乙胺和异丙胺等胺类。

  DOI：

  10.1271/bbb.100199
• 作为产物：
  描述：

  N-benzyloxycarbonyl-L-glutamic acid-5-hydrazide 在 甲醇 、 氯仿 、 钯 作用下， 生成 N-L-gamma-谷氨酰-L-亮氨酸
  参考文献：
  名称：

  755. Amino-acids and peptides. Part IX. γ-L-Glutamyl-L-alanine, -L-valine, and -L-leucine

  摘要：

  DOI：

  10.1039/jr9520003937

文献信息

• [EN] CELLULAR TRANSPORT SYSTEM FOR TRANSFERRING A SULFONIC ACID CONSTRUCT CARRYING A CARGO INTO THE CYTOPLASM OF A CELL<br/>[FR] SYSTÈME DE TRANSPORT CELLULAIRE PERMETTANT DE TRANSFÉRER UNE CONSTRUCTION D'ACIDE SULFONIQUE PORTANT UN CARGO DANS LE CYTOPLASME D'UNE CELLULE
  申请人：SCIENTIST OF FORTUNE SA

  公开号：WO2019068726A1

  公开（公告）日：2019-04-11

  The present invention relates to a cellular transport system for bringing a sulfonic acid construct which carries a cargo into a cell and releasing the cargo in the cell's cytoplasm, the cellular transport system comprising: (i) a sulfonate transporter located in the cytoplasm membrane of the cell wherein said sulfonate transporter is capable of transporting said sulfonic acid construct across the cytoplasm membrane into the cytoplasm; (ii) a γ-glutamyl transferase (GGT; EC 2.3.2.2) which is modified to be located in the cytoplasm of the cell, wherein said γ-glutamyl transferase is capable of hydrolyzing said sulfonic acid construct so as to release the cargo. Moreover, the present invention relates to the use of a cellular transport system for bringing a sulfonic acid construct which contains a cargo into a cell and releasing the cargo in the cell's cytoplasm. Further, the present invention relates to a γ-glutamyl transferase for hydrolyzing a sulfonic acid construct which contains a cargo.

  本发明涉及一种细胞运输系统，用于将携带货物的磺酸构造体带入细胞并在细胞质中释放货物，所述细胞运输系统包括：（i）位于细胞质膜中的磺酸转运蛋白，其中所述磺酸转运蛋白能够将所述磺酸构造体跨越细胞质膜运输至细胞质；（ii）改性为位于细胞质中的γ-谷氨酰转移酶（GGT；EC 2.3.2.2），其中所述γ-谷氨酰转移酶能够水解所述磺酸构造体以释放货物。此外，本发明涉及使用细胞运输系统将携带货物的磺酸构造体带入细胞并在细胞质中释放货物。此外，本发明涉及用于水解携带货物的磺酸构造体的γ-谷氨酰转移酶。
• TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY
  申请人：Jung Francoise

  公开号：US20120283168A1

  公开（公告）日：2012-11-08

  Novel template-fixed β-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are α-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to antagonize the receptor CCR10. They can be used as medicaments to treat or prevent diseases or conditions in the area of dermatological and cutaneous disorders, inflammation, allergic disorders, respiratory diseases, diseases of the gastro-intestinal tract, ophthalmic diseases, haematology and cancer. These β-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.

  具有以下一般式(I)的小说模板固定β-发夹仿生肽，其中单个元素T或P是α-氨基酸残基，可以连接在任何方向上，具体取决于它们在链中的位置，如描述和索赔中所定义，及其盐，具有拮抗受体CCR10的特性。它们可用作药物，用于治疗或预防皮肤病和皮肤疾病、炎症、过敏性疾病、呼吸道疾病、胃肠道疾病、眼科疾病、血液学和癌症等领域。这些β-发夹仿生肽可以通过基于混合固相和溶液相合成策略的过程制备。
• Enzymatic Synthesis of γ‐Glutamyl Dipeptides Catalysed by Mutant <i>E. coli</i> γ‐Glutamyltransferases
  作者：Marco Rabuffetti、Giovanna Speranza、Cinzia Calvio、Carlo F. Morelli

  DOI：10.1002/ejoc.202200907

  日期：2022.11.18

  identified inside the active site of E. coli γ-glutamyltransferase, putatively involved in acceptor substrate binding. Point-mutation of these residues afforded two mutant enzymes with altered catalytic properties. Mutant T413L showed a very promising transpeptidation-to-hydrolysis ratio up to 20 : 1. The two mutants were tested as biocatalysts for the enzymatic synthesis of γ-glutamyl dipeptides with flavor-enhancer

  在大肠杆菌γ-谷氨酰转移酶的活性位点内鉴定出两个残基，推测与受体底物结合有关。这些残基的点突变提供了两种催化特性改变的突变酶。突变体 T413L 显示出非常有希望的高达 20:1 的转肽水解比。这两个突变体被测试为用于酶促合成具有增味特性的 γ-谷氨酰二肽的生物催化剂。
• Reagents for assay of gamma-glutamyl-transpeptidase
  申请人：UNITIKA LTD.

  公开号：EP0266905A1

  公开（公告）日：1988-05-11

  A reagent for assaying γ-glutamyltranspeptidase (γ-GTP) which contains an amino acid dehydrogenase and a substrate specific to γ-glutamyltranspeptidase activity. The reagent can be used to assay the γ-GTP activity directly from the continuous course of reaction without using a standard substance with known activity. The procedure required is simple and easy, and the reagent is capable of determining γ-GTP activity with good accuracy and without affecting by interfering substances, making it satisfactory for routine use in clinical laboratories.

  一种用于测定γ-谷氨酰转肽酶（γ-GTP）的试剂，它含有氨基酸脱氢酶和对γ-谷氨酰转肽酶活性有特异性的底物。该试剂无需使用已知活性的标准物质，即可直接从连续反应过程中检测 γ-GTP 活性。该试剂所需的步骤简单易行，能够准确测定 γ-GTP 活性，且不受干扰物质的影响，因此非常适合临床实验室的常规使用。
• Biomarkers for fatty liver disease and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2546649A2

  公开（公告）日：2013-01-16

  The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

  本发明提供了脂肪肝的各种生物标志物，包括脂肪变性和脂肪性肝炎。本发明还提供了使用这些生物标志物的各种方法，包括诊断脂肪肝的方法、确定脂肪肝易感性的方法、监测脂肪肝进展/恶化的方法、评估治疗脂肪肝组合物疗效的方法、筛选组合物调节脂肪肝生物标志物活性的方法、治疗脂肪肝的方法以及基于脂肪肝生物标志物的其他方法。